52
Participants
Start Date
March 3, 2022
Primary Completion Date
November 16, 2023
Study Completion Date
November 20, 2023
LP352
LP352 administered three times daily, orally or through G-tube
Placebo
Matching placebo for LP352 administered three times daily, orally or through G-tube
Alfred Health, Melbourne
Austin Health, Heidelberg
Monash Children's Hospital, Monash Health, Clayton
Royal Brisbane Women's Hospital, Herston
Queensland Children's Hospital, South Brisbane
Northwell Health, New York
Northeast Regional Epilepsy Group, Staten Island
Boston Children's Health Physicians LLP, Hawthorne
New York University Langone Hospital - Long Island, Mineola
Mid-Atlantic Epilepsy and Sleep Center, Bethesda
Wake Forest University School of Medicine, Winston-Salem
Northwest Florida Clinical Research Group, Gulf Breeze
Advent Health Orlando, Orlando
Research Institute of Orlando, Orlando
University of Miami, Miami
University of South Florida, Tampa
University Hospitals Cleveland Medical Center, Cleveland
Spectrum Health, Grand Rapids
Mayo Clinic, Rochester
Northwestern University Feinberg School of Medicine, Chicago
Washington University School of Medicine, St Louis
Arkansas Children's Hospital, Little Rock
Child Neurology Consultants of Austin, Austin
Austin Epilepsy Care Center, Austin
Consultants in Epilepsy and Neurology, Boise
University of Utah, Salt Lake City
University of Arizona - Health Sciences Center, Tucson
Rancho Los Amigos National Rehabilitation Center (RLANRC), Downey
Children's Hospital of Orange County, Orange
University of California San Francisco, San Francisco
Hawaii Pacific Neuroscience, Honolulu
Providence Neurological Specialties-East, Portland
University of Washington Valley Medical Center, Renton
OnSite Clinical Solutions LLC, Charlotte
Lead Sponsor
Longboard Pharmaceuticals
INDUSTRY